On Tuesday, Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) opened higher 3.31% from the last session, before settling in for the closing price of $20.86. Price fluctuations for KNSA have ranged from $16.56 to $28.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 140.87%. Company’s average yearly earnings per share was noted 184.80% at the time writing. With a float of $40.16 million, this company’s outstanding shares have now reached $41.88 million.
Let’s determine the extent of company efficiency that accounts for 315 employees. In terms of profitability, gross margin is 85.54%, operating margin of -10.78%, and the pretax margin is -8.54%.
Kiniksa Pharmaceuticals International Plc (KNSA) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Kiniksa Pharmaceuticals International Plc is 44.72%, while institutional ownership is 54.48%. The most recent insider transaction that took place on Mar 10 ’25, was worth 261,330. Before that another transaction happened on Feb 10 ’25, when Company’s CHIEF OPERATING OFFICER sold 14,000 for $19.57, making the entire transaction worth $273,980. This insider now owns 81,975 shares in total.
Kiniksa Pharmaceuticals International Plc (KNSA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 184.80% per share during the next fiscal year.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Trading Performance Indicators
Check out the current performance indicators for Kiniksa Pharmaceuticals International Plc (KNSA). In the past quarter, the stock posted a quick ratio of 3.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.70. Likewise, its price to free cash flow for the trailing twelve months is 61.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit 0.04 in the next quarter and is forecasted to reach 1.00 in one year’s time.
Technical Analysis of Kiniksa Pharmaceuticals International Plc (KNSA)
Looking closely at Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA), its last 5-days average volume was 0.81 million, which is a jump from its year-to-date volume of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 67.50%. Additionally, its Average True Range was 0.90.
During the past 100 days, Kiniksa Pharmaceuticals International Plc’s (KNSA) raw stochastic average was set at 36.11%, which indicates a significant decrease from 77.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.23% in the past 14 days, which was lower than the 45.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.87, while its 200-day Moving Average is $22.13. However, in the short run, Kiniksa Pharmaceuticals International Plc’s stock first resistance to watch stands at $21.94. Second resistance stands at $22.32. The third major resistance level sits at $23.10. If the price goes on to break the first support level at $20.78, it is likely to go to the next support level at $20.00. Should the price break the second support level, the third support level stands at $19.62.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Key Stats
There are currently 72,644K shares outstanding in the company with a market cap of 1.57 billion. Presently, the company’s annual sales total 423,240 K according to its annual income of -43,190 K. Last quarter, the company’s sales amounted to 122,540 K and its income totaled -8,890 K.
